Ralliant Corp (RAL) Stock News

Grail, spun off from Illumina in 2024, develops the Galleri blood test for early cancer detection. The company has grown revenue from $93M (2023) to $147M (2025) through cash-only sales and is expected to reach $181M in 2026. An FDA panel recently endorsed premarket approval with three affirmative votes, potentially supporting FDA approval by 2027. Despite trading at 21x 2028 sales, analysts believe the stock could be undervalued if FDA approval comes early and adoption accelerates.

Trio Petroleum Corp acquired 24 oil wells (4 producing, 20 shut-in) from Marlin Resources Ltd in Saskatchewan's Lloydminster region for CDN$800,000 cash plus an underutilized water disposal asset. The acquisition includes 37 BOPD of current production, a planned Cummings multilateral well with CDN$1.2 million development budget, and a CDN$425,000 workover program. The company expects the purchase price per flowing barrel to be discounted compared to market rates for comparable assets.

Hagens Berman has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) alleging the company misled investors about its NHS-Galleri cancer screening trial's design and efficacy. GRAIL failed to meet the trial's primary endpoint on February 19, 2026, causing the stock to plummet 50.55% and erasing $2.2 billion in market capitalization. The lead plaintiff deadline is August 4, 2026.

Grail's stock has declined from a record high of $116.06 to under $70 following a failed NHS England trial for its Galleri blood cancer test. However, the company continues generating revenue ($147M in 2025) through direct-to-consumer sales and is expected to grow to $281M by 2028. Despite the setback, analysts recommend holding the stock as an FDA approval could significantly boost growth prospects.

Rosen Law Firm reminds investors in GRAIL, Inc. (NASDAQ: GRAL) who purchased shares between May 13, 2025 and February 19, 2026 of the August 4, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that defendants made misleading statements about the NHS-Galleri trial results and concealed material negative facts about the trial's ability to demonstrate cancer reduction in stages III-IV, causing investor losses.

Rosen Law Firm reminds GRAIL, Inc. investors who purchased stock between May 13, 2025 and February 19, 2026 of the August 4, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that GRAIL provided misleading statements about its NHS-Galleri trial results, concealing that the trial period was insufficient to demonstrate the primary endpoint of reducing Stage III-IV cancers.

The Gross Law Firm has issued a shareholder alert for GRAIL, Inc. (NASDAQ: GRAL) regarding a securities class action lawsuit. The lawsuit alleges that GRAIL provided misleading statements about its NHS-Galleri trial, concealing that the trial period was insufficient to demonstrate reduction in Stage III-IV cancers. On February 19, 2026, GRAIL announced the primary endpoint was not achieved, causing the stock to plummet 50.55% in a single day from $101.53 to $50.21. The deadline for lead plaintiff registration is August 4, 2026.

Law firm Robbins Geller has filed class action lawsuits against GRAIL, Inc., GPGI, Inc., and Wix.com Ltd., alleging that executives made false and misleading statements to investors. GRAIL investors can seek lead plaintiff status by August 4, 2026, following a 50% stock price decline after the company failed to achieve primary endpoints in its NHS-Galleri cancer screening trial.

Rosen Law Firm announces a securities class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) on behalf of investors who purchased shares between May 13, 2025 and February 19, 2026. The lawsuit alleges that GRAIL made false and misleading statements regarding its NHS-Galleri cancer screening trial, concealing that the three-year follow-up period was insufficient to demonstrate stage III-IV cancer reduction and withholding detailed preliminary results that may have shown unfavorable trends.

A securities class action lawsuit has been filed against GRAIL, Inc. for allegedly providing misleading statements about its NHS-Galleri cancer screening trial. The lawsuit claims defendants concealed material adverse facts about the trial's ability to demonstrate a reduction in Stage III-IV cancers. Investors who purchased GRAIL stock between May 13, 2025 and February 19, 2026 may be eligible for compensation. The deadline to serve as lead plaintiff is August 4, 2026.

Hagens Berman has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) alleging the company misled investors about its NHS-Galleri cancer screening trial's design and efficacy. GRAIL failed to meet the trial's primary endpoint on February 19, 2026, and admitted the three-year follow-up period was insufficient. The stock collapsed 50.55% in a single trading session, erasing $2.2 billion in market capitalization. The lead plaintiff deadline is August 4, 2026.

GRAIL, Inc. faces a securities fraud class action lawsuit after its stock plummeted 50% on February 20, 2026, following the announcement that its NHS-Galleri cancer trial failed to meet its primary endpoint of reducing late-stage cancers. Investors allege the company misrepresented the trial's design and results, claiming the three-year timeframe was insufficient to achieve the stated objective. The lead plaintiff deadline is August 4, 2026.

Rosen Law Firm is soliciting investors who suffered losses in GRAIL, Inc., First Solar, Inc., and Gildan Activewear Inc. to join securities class action lawsuits. The primary case involves GRAIL, Inc., where defendants allegedly made materially false statements about their NHS-Galleri trial results and concealed adverse facts about the trial's ability to demonstrate cancer reduction outcomes. The lead plaintiff deadline is August 4, 2026.

A securities class action lawsuit has been filed against GRAIL, Inc. for allegedly providing misleading statements about its NHS-Galleri trial results. The company allegedly concealed material adverse facts about the trial's ability to demonstrate a reduction in Stage III-IV cancers. Investors who purchased GRAIL common stock between May 13, 2025 and February 19, 2026 may be eligible for compensation. The deadline to serve as lead plaintiff is August 4, 2026.

Hagens Berman is investigating GRAIL, Inc. for allegedly misleading investors about its NHS-Galleri cancer screening trial. The company failed to disclose that a three-year follow-up period was insufficient to meet the trial's primary endpoint. When GRAIL revealed the trial failure on February 19, 2026, its stock collapsed 50.55%, erasing $2.2 billion in market capitalization. The class action covers the period from May 13, 2025 to February 19, 2026, with a lead plaintiff deadline of August 4, 2026.

Hagens Berman is investigating GRAIL, Inc. for allegedly misleading investors about its NHS-Galleri cancer screening trial. The company failed to disclose that a three-year follow-up period was insufficient to meet the trial's primary endpoint. When GRAIL revealed the trial failure on February 19, 2026, its stock collapsed 50.55%, erasing $2.2 billion in market capitalization. The class action period spans May 13, 2025 to February 19, 2026, with a lead plaintiff deadline of August 4, 2026.

Law firm Robbins Geller Rudman & Dowd LLP announced class action lawsuits against GRAIL, Inc. (NASDAQ: GRAL) for allegedly making false statements about its NHS-Galleri cancer screening trial. GRAIL failed to achieve the primary endpoint of reducing Stage III-IV cancers, causing the stock to fall over 50% on February 19, 2026. The firm is seeking lead plaintiffs from investors who purchased GRAL stock between May 13, 2025 and February 19, 2026. Similar lawsuits were also filed against Commvault Systems, Inc. and PicS N.V.

Grail, Inc. (NASDAQ: GRAL) faces a class action securities fraud lawsuit after failing to meet the primary endpoint in its NHS-Galleri cancer trial on February 19, 2026. The announcement caused the stock to plummet 50.5%. Investors allege the company made materially false statements about trial results and failed to disclose that the three-year timeline was insufficient to demonstrate the primary endpoint, misleading shareholders about business prospects.

A securities class action lawsuit has been filed against GRAIL, Inc. alleging that defendants made materially false and misleading statements regarding their NHS-Galleri trial results. The company allegedly concealed that the trial period was insufficient to demonstrate the primary endpoint of reducing Stage III-IV cancers. Investors who purchased GRAIL common stock between May 13, 2025 and February 19, 2026 may be eligible for compensation. The lead plaintiff deadline is August 4, 2026.

A federal securities class action has been filed against Grail, Inc. (NASDAQ: GRAL) alleging that company executives made false and misleading statements about the NHS-Galleri cancer detection trial's likelihood of success while concealing material adverse facts. On February 19, 2026, Grail announced the trial failed to achieve its primary endpoint, causing the stock to plummet 50.55% in a single day from $101.53 to $50.21 per share. Investors who purchased GRAL stock between May 13, 2025 and February 19, 2026 may be eligible to participate in the class action, with a deadline of August 4, 2026 to seek lead plaintiff appointment.

Berger Montague has filed a class action lawsuit against GRAIL, Inc. on behalf of investors who purchased stock between May 13, 2025 and February 19, 2026. The lawsuit alleges that GRAIL failed to disclose that the NHS-Galleri trial was insufficient to demonstrate the primary endpoint of reducing Stage III-IV cancers. On February 19, 2026, GRAIL announced the trial's primary endpoint had not been met, causing the stock to plummet approximately 50.55% in a single trading day from $101.53 to $50.21 per share. The lead plaintiff deadline is August 4, 2026.

A securities class action lawsuit has been filed against GRAIL, Inc. alleging that defendants made materially false and misleading statements regarding their NHS-Galleri trial results. The complaint claims defendants provided overly positive statements while concealing material adverse facts about the trial's ability to demonstrate a reduction in Stage III-IV cancers. Investors who purchased GRAIL common stock between May 13, 2025 and February 19, 2026 may be entitled to compensation. The lead plaintiff deadline is August 4, 2026.

GRAIL, Inc. lost over $2.2 billion in market capitalization on February 20, 2026, after its NHS-Galleri trial failed to meet its primary endpoint for early cancer detection. A securities class action lawsuit alleges the company misled investors about the trial's design and likelihood of success, claiming management knew a three-year follow-up period would be insufficient but expressed high confidence anyway. The stock plunged over 50% following the announcement.

Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Badger Meter, Grail, Inc., and PicS N.V. The lawsuits allege materially false statements and/or failure to disclose material facts. Badger Meter faces allegations regarding order pull-forward practices, Grail regarding its NHS-Galleri trial, and PicS regarding credit evaluation procedures in its IPO. Investors who suffered losses during the relevant periods are encouraged to seek lead plaintiff status.

GRAIL, Inc. faced a securities class action lawsuit after its NHS-Galleri trial failed to meet its primary endpoint on February 20, 2026, resulting in a $2.2 billion market capitalization loss and over 50% stock price decline. The lawsuit alleges GRAIL misled investors about the trial's design and likelihood of success, with the company later admitting it should have allowed for a longer follow-up period than the three years originally touted.

Rosen Law Firm is reminding investors who purchased GRAIL, Inc. common stock between May 13, 2025 and February 19, 2026 of an important August 4, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that GRAIL provided overwhelmingly positive statements while concealing material adverse facts about its NHS-Galleri trial, specifically that the trial period was insufficient to demonstrate the achievability of reducing Stage III-IV cancers and that the company refused to provide detailed results.

Faruqi & Faruqi, LLP is investigating securities fraud claims against Grail, Inc. (NASDAQ: GRAL) for allegedly making false and misleading statements about its NHS-Galleri cancer detection trial. The company touted confidence in the trial's success while concealing that the three-year trial period was insufficient to achieve its primary endpoint. On February 19, 2026, Grail announced the primary endpoint was not met, causing the stock to plummet 50.55% in a single day from $101.53 to $50.21 per share. Investors who purchased GRAL stock between May 13, 2025 and February 19, 2026 may be eligible to participate in the class action, with a deadline of August 4, 2026 to seek lead plaintiff appointment.

Rosen Law Firm is reminding investors in GRAIL, Inc. (NASDAQ: GRAL) who purchased stock between May 13, 2025 and February 19, 2026 of an August 4, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that GRAIL provided misleading statements about its NHS-Galleri trial results, concealing material adverse facts about the trial's ability to demonstrate cancer reduction outcomes. Investors may be eligible for compensation through a contingency fee arrangement.

Robbins LLP has filed a class action lawsuit against Grail, Inc. (NASDAQ: GRAL) on behalf of investors who purchased securities between May 13, 2025 and February 19, 2026. The lawsuit alleges that Grail misled investors about the success probability of its NHS-Galleri trial, which failed to achieve its primary endpoint. Following the announcement on February 19, 2026, Grail's stock price plummeted approximately 50.55% in a single trading day, from $101.53 to $50.21 per share.

GRAIL, Inc. lost over $2.2 billion in market capitalization on February 20, 2026, after its NHS-Galleri trial failed to meet its primary endpoint for early cancer detection. A securities class action lawsuit alleges the company misled investors about the trial's design and likelihood of success, claiming GRAIL had internal information suggesting three years would be insufficient for the trial but expressed high confidence anyway. The stock plunged over 50% following the announcement.